Stimuli-responsive drug delivery: companies, startups and research

University of Sichuan and Chinese Academy of Sciences CAS are prominent contributors, with 164 and 144 documents, respectively, in the 24-month window. Chitkara University is also active, with 99 documents, while Zhejiang University is associated with light-activated systems. Recent work spans responsive hydrogels, nanocarriers and coacervates, with applications including cancer therapy, inflammation and wound care.

The records list $22,792,180 across 63 grants since 2020, plus 10 funding rounds totaling $689,025,182. These are topic-associated funding figures, not necessarily funds dedicated solely to stimuli-responsive delivery. The rounds include entries for institutions such as University of Oxford and Harvard University, so individual records should be checked before treating them as direct support for a specific platform.

Zhejiang University and University Of Pittsburg Of The Commonwealth System Of Higher Education lead the listed patent holders, with 2 patents each. Harvard University, Stanford University and Cornell University each have 1 listed patent, as do the French National Center for Scientific Research and the French Institute of Health and Medical Research. The counts are modest and describe the patent-holder records available for this topic.

No: 28 patents appear in the 24-month window, and patent activity declined 52.6% in the last 12 months versus the previous 12 months. By contrast, publications reached 3,714 in the last year, up 49.8%. This divergence suggests that research output is expanding faster than recent patent filings, although the two measures capture different kinds of activity.

The records suggest a research-heavy field still facing a substantial translation challenge: they include 2,699 research organizations and 1 clinical trial. Work ranges from responsive polymers and hydrogels to targeted nanocarriers, but publication activity alone does not establish clinical readiness. Device integration, reproducible release behavior and performance in complex biological environments remain important considerations for developers.

October 2026 work includes an AI-guided PSMA-targeted nanoplatform for prostate cancer and a triple-stimuli-responsive succinoglycan hydrogel with antioxidant activity. In September 2026, researchers reported pathological-signal-responsive delivery approaches for sepsis and a hybrid magnetic system for pH-responsive release. August 2026 studies explored a programmable three-state tumor nanoreactor and photothermally triggered pulsatile release from dynamic-covalent PEG hydrogels.

The main approaches are endogenous biochemical, thermal, light-activated, acoustic, and magnetic or electrical triggers. Endogenous systems use cues such as pH or redox conditions; external triggers offer more direct control but may require light access, ultrasound or a device. Endogenous biochemical triggers lead by document volume, with 4,743 documents, while acoustic and magnetic or electrical approaches show recent activity growth.

China leads with 11,767 documents, or 45.2% of the recorded total. The United States follows with 3,735 documents, and India has 3,357. Other active countries include Iran, South Korea and the United Kingdom. These figures indicate where topic-related research and other records are concentrated; they do not by themselves measure commercial deployment or clinical adoption.

Cancer therapy is the largest listed application, with 4,433 documents; infection and wound care has 1,735, and regenerative medicine has 1,169. The records also cover neurological disorders and diabetes and metabolic disease. Recent work includes responsive systems for sepsis, lung injury and spinal cord injury, illustrating how researchers are extending trigger-based release beyond cancer applications.